Table 1.

Patient demographics and baseline disease/clinical characteristics

	Arm 1 (lete-cel) (N = 3)	Arm 2 (lete-cel + pembrolizumab) (N = 3)	Total (N = 6)
Median age, y (range)	60.0 (59-79)	64.0 (62-67)	63.0 (59-79)
Male sex, n (%)	3 (100)	3 (100)	6 (100)
HLA status, n (%)
HLA-A∗02:01–positive	3 (100)	3 (100)	6 (100)
NY-ESO-1/LAGE-1a status, n (%)∗
NY-ESO-1–positive	2 (67)	2 (67)	4 (67)
LAGE-1a–positive	3 (100)	2 (67)	5 (83)
Median time from initial diagnosis to screening, mo (range)†	n = 1 50.7 (50.7-50.7)	n = 2 30.2 (7.3-53.1)	n = 3 50.7 (7.3-53.1)
Disease stage at initial diagnosis, n (%)
Stage I/II	1 (33)	0	1 (17)
Stage III	1 (33)	1 (33)	2 (33)
Unknown	1 (33)	2 (67)	3 (50)
History of autologous HCT, n (%)
Yes	1 (33)	1 (33)	2 (33)
Adverse cytogenetics, n (%)‡	n = 1	n = 3	n = 4
t(4;14)	0	2 (67)	2 (50)
1q amplification	1 (100)	2 (67)	3 (75)
Prior number of systemic therapy regimens, n (%)
2	0	1 (33)	1 (33)
3	2 (67)	0	2 (67)
5	0	2 (67)	2 (67)
≥6	1 (33)	0	1 (33)
Prior exposure to, n (%)
Immunomodulatory agents
Lenalidomide	3 (100)	3 (100)	6 (100)
Pomalidomide	3 (100)	3 (100)	6 (100)
PIs
Bortezomib	3 (100)	3 (100)	6 (100)
Carfilzomib	3 (100)	3 (100)	6 (100)
Anti-CD38 mAb
Daratumumab	3 (100)	3 (100)	6 (100)

Patient demographics and disease characteristics at screening for the mITT population, including all patients who received lete-cel.

mITT, modified ITT; N, patients in mITT population; n, patients with available data.

^∗Eligible patients could have NY-ESO-1– and/or LAGE-1a–positive status.

^†Median time from diagnosis to screening is only provided for patients with complete diagnosis dates. Three patients had partial diagnosis dates and therefore were excluded from this row.

^‡Patients could have more than 1 adverse cytogenetic feature.